KYMERA THERAP.INC. -,0001

Kymera Therapeutics said it finished enrollment in the Phase 2b KT-621 atopic dermatitis trial about six months ahead of schedule, with top-line data expected by the end of 2026 and potential Phase 3 initiation around mid-2027. The KT-621 asthma Phase 2b study is enrolling with results expected in late 2027 and an open-label extension available for completers. Kymera expects Phase 1 data for oral IRF5 degrader KT-579 in Q4 2026 and plans a lupus proof-of-concept study thereafter. The company reported $65 million of Q2 collaboration revenue and held about $1.5 billion in cash and investments, providing a runway into 2029. » More on finance.yahoo.com

Kymera Therapeutics will publish results for the quarter ended June 30, 2026, on 05.08.2026; analyst consensus expects a loss per share of $0.713 (prior year: $0.950). Estimated revenues average $32.8 million, well above last year’s $11.5 million (+185.5%). For the fiscal year analysts forecast a mean EPS loss of $3.465 and revenues of about $85.4 million (prior year: $39.2 million). » More on finanzen.net

Kymera Therapeutics has appointed Dr. Terence Rooney as chief medical officer. Rooney will lead the global clinical development strategy and advance the portfolio of oral immunology programs. He succeeds Dr. Jared Gollob, who is retiring after eight years and will remain as an advisor through the end of the year. Rooney joins from Johnson & Johnson and brings extensive leadership experience from J&J, Eli Lilly and Roche. » More on de.investing.com